Novo says CagriSema beats Lilly rival on weight loss in diabetes
The head-to-head claim pits Novo Nordisk's cagrilintide-semaglutide combination against Eli Lilly's incretin drug in patients with type 2 diabetes.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 21 09:22 ETSource: Reuters
The wire
- 01Novo Nordisk said its CagriSema, a combination of the amylin analog cagrilintide and semaglutide, produced greater weight loss than Eli Lilly's competing drug in people with type 2 diabetes.
- 02A win in diabetes patients, where weight loss is typically smaller than in obesity trials, would strengthen CagriSema's position as Novo seeks ground back from Lilly.
- 03The comparison comes from the company; full trial data, safety and tolerability details and regulatory timing remain to be seen.
From the source
Read at reuters.comNovo says CagriSema shows greater weight loss than Lilly rival in diabetes patients